AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01969084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01332318
Drug: XP13512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP13512 once daily for 16 days
Trial: NCT01332318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP13512 placebo once daily for 16 days
Trial: NCT01361789
Drug: parecoxib, valdecoxib, etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery
Trial: NCT01361789
Drug: parecoxib, valdecoxib, parecoxib and dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of both drugs
Trial: NCT00579475
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00525200
Drug: 5-Fluoruracil, Cisplatinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21
Trial: NCT01958047
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04475016
Drug: Triprilimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg IV on Day 1
Trial: NCT02901301
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, PO, BID, Day 1-14
Trial: NCT03721900
Drug: SHX-001 Active low dose
RxNorm normalized name: eptacog alfa activated 0.001 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine transdermal patch
Trial: NCT03721900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal patch
Trial: NCT03721900
Drug: SHX-001 Active High dose
RxNorm normalized name: eptacog alfa activated 0.001 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine transdermal patch
Trial: NCT01350388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet per day for 24 weeks
Trial: NCT03904368
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin stimulation of follicular growth
Trial: NCT02770768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
Trial: NCT04312594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered Placebo taken orally as tablets twice daily
Trial: NCT04357587
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 orally twice a day on days where radiation therapy is given
Trial: NCT00928876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo s/c daily for four weeks
Trial: NCT00860522
Drug: JVRS-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
Trial: NCT00860522
Drug: JVRS-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
Trial: NCT03669484
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
Trial: NCT02338310
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of AI is according to centre policy; any brand can be used
Trial: NCT03392779
Drug: ZSP1601 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 tablet administered orally once daily under fasted condition
Trial: NCT03392779
Drug: Placebo 175 mg
RxNorm normalized name: Ascorbic Acid/Cyanocobalamin/Docusate Sodium/Folic Acid/Iron/Succinic Acid/Zinc;Placebo 175 MG-12 MCG-50 MG-1 MG-75 MG-150 MG-10 MG; NA Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
Trial: NCT02685072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNP + Placebo
Trial: NCT03392779
Drug: Placebo 275 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
Trial: NCT03392779
Drug: ZSP1601 350 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 tablets administered orally once daily under fasted condition
Trial: NCT03903367
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
Trial: NCT03392779
Drug: Placebo 350mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
Trial: NCT03392779
Drug: Placebo 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
Trial: NCT01210352
Drug: oxymorphone HCl
RxNorm normalized name: oxymorphone HCl
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
Trial: NCT01689233
Drug: TRx0237 200 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRx0237 100 mg tablets will be administered twice daily.
Trial: NCT01689233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Trial: NCT03392779
Drug: ZSP1601 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Trial: NCT01442727
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
Trial: NCT00681265
Drug: polyethylene glycol 400/propylene glycol
RxNorm normalized name: POLYETHYLENE GLYCOL 400/PROPYLENE GLYCOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
Trial: NCT02717442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of placebo
Trial: NCT03412006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Trial: NCT03392779
Drug: Placebo 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Trial: NCT00382109
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00382109
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03392779
Drug: ZSP1601 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Trial: NCT03392779
Drug: Placebo 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
Trial: NCT01780584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
Trial: NCT01780584
Drug: Oral T3 high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
Trial: NCT01039805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01039805
Drug: GSK962040 (75 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 = 75 mg
Trial: NCT01126177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (excipients of the SNG001 solution only)
Trial: NCT04401280
Drug: CPP-ACP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: applied in accordance with the manufacturer's specifications
Trial: NCT01464671
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulation during percutaneous coronary intervention
Trial: NCT01187264
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
Trial: NCT00332631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04174365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily for up to Week 8.
Trial: NCT01590849
Drug: Contraceptives, Oral, Combined (Yaz®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use.
Trial: NCT01554163
Drug: Etoricoxib 30 mg
RxNorm normalized name: Etoricoxib 30 mg oral tablet
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 30 mg tablet once daily for 12 weeks.
Trial: NCT01554163
Drug: Celecoxib 200 mg
RxNorm normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg once daily for 12 weeks
Trial: NCT02427802
Drug: Gentamicin collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Trial: NCT00937092
Drug: low-dose dopamine + low-dose furosemide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
Trial: NCT03010241
Drug: Tangbi (prescription)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Trial: NCT03010241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Trial: NCT02232555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00481013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
Trial: NCT00516490
Drug: Na Cl %0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
Trial: NCT01281943
Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle
Trial: NCT00224406
Drug: Repertaxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
Trial: NCT02954458
Drug: TED
RxNorm normalized name: Meted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg SC injection once daily.
Trial: NCT00095459
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00307853
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
Trial: NCT01147003
Drug: Investigational new drug, company code: BGG492
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01147003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00639392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
Trial: NCT00639392
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
Trial: NCT02083653
Drug: Sym004 (12 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Trial: NCT02083653
Drug: Sym004 (9/6 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
Trial: NCT00688545
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Trial: NCT02083653
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Trial: NCT02083653
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
Trial: NCT00940641
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Dose
Trial: NCT00940641
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose
Trial: NCT04876976
Drug: Cyanoacrylate, Isobutyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
Trial: NCT00897975
Drug: phytosterol
RxNorm normalized name: Phytosterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phytosterol 450 mg 2 tabs bid with food
Trial: NCT00897975
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00688545
Drug: nsNSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Trial: NCT00282152
Drug: Optimal drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
Trial: NCT02929134
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
Trial: NCT02929134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Trial: NCT03391804
Drug: ALLN-177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
Trial: NCT00752869
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet per day for 1 year
Trial: NCT00856843
Drug: BLI800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for oral administration prior to colonoscopy
Trial: NCT01892904
Drug: EE20/DRSP(BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
Trial: NCT02035553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two tablets, once daily by mouth
Trial: NCT03019991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
Trial: NCT03358706
Drug: Caffeine 100 mg
RxNorm normalized name: caffeine 100 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
Trial: NCT03825068
Drug: general anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient receive general anaesthetic only
Trial: NCT01854697
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT01014247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching tablet
Trial: NCT02335255
Drug: Placebo Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Trial: NCT02946892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given for 12 weeks and then an exercise test will be performed
Trial: NCT03257241
Drug: B arm (DAC)
RxNorm normalized name: Zodryl DAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
Trial: NCT03257241
Drug: B arm (FLAG-IDA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol.
Trial: NCT02342977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will randomly receive placebo
Trial: NCT01078298
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets matched in appearance and dosage to varenicline tablets
Trial: NCT03489941
Drug: Zaditor®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.